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Abstract
An important task in drug development is to identify patients, which respond better or
worse to an experimental treatment. Identifying predictive covariates, which influence the
treatment effect and can be used to define subgroups of patients, is a key aspect of this task.
Analyses of treatment effect heterogeneity are however known to be challenging, since the
number of possible covariates or subgroups is often large, while samples sizes in earlier phases
of drug development are often small. In addition, distinguishing predictive covariates from
prognostic covariates, which influence the response independent of the given treatment, can
often be difficult.
While many approaches for these types of problems have been proposed, most of them fo-
cus on the two-arm clinical trial setting, where patients are given either the treatment or a
control. In this paper we consider parallel groups dose-finding trials, in which patients are
administered different doses of the same treatment.
To investigate treatment effect heterogeneity in this setting we propose a Bayesian hierarchi-
cal dose-response model with covariate effects on dose-response parameters. We make use of
shrinkage priors to prevent overfitting, which can easily occur, when the number of considered
covariates is large and sample sizes are small. We compare several such priors in simulations
and also investigate dependent modeling of prognostic and predictive effects to better dis-
tinguish these two types of effects. We illustrate the use of our proposed approach using a
Phase II dose-finding trial and show how it can be used to identify predictive covariates and
subgroups of patients with increased treatment effects.
Keywords: dose estimation; horseshoe; nonlinear models, personalised medicine, shrinkage priors
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1 Introduction
Investigating possible heterogeneity of treatment effects is an important task in Phase II and Phase
III randomized clinical trials and can help identifying groups of patients, for which treatment effects
are higher than for the rest of the population. By identifying such subgroups and possibly designing
future clinical trials to confirm these findings, sponsors can increase the chance of success for later
trials and patients can receive a treatment, that is particularly effective for them. From a statistical
perspective analyses of treatment effect heterogeneity with the aim of identifying a promising
subgroup are however known to be challenging. A large number of possible subgroups leads to
multiplicity issues, in addition treatment effect estimates in selected subgroups are biased (due to
the selection) and sample sizes are often not adequate for detecting treatment effect heterogeneity.
A high-level overview of the involved statistical challenges, but also opportunities is given in [1].
Commonly baseline covariates, which have been measured before the start of the trial, are used
to define subgroups. These covariates can be demographic, clinical or genetic and are usually
prespecified. When treatment effect heterogeneity is investigated, one usually aims at identifying
predictive covariates, which modify the response to the administered treatment, instead of just
prognostic covariates which modify the response independent of any treatment. Distinguishing
prognostic and predictive effects can often be a challenging issue [2]. If covariates are identified as
predictive, they can be used to define subgroups with increased treatment effects.
A large number of methods for identifying predictive covariates and subgroups have been pro-
posed in recent years. Due to their ability to handle high-order interactions and their good inter-
pretability, many of the proposed approaches employ tree-based partitionings of the overall trial
data [3, 4, 5, 6, 7, 8]. Other statistical approaches to the problem include Bayesian model averaging
[9] and penalized regression [10, 11]. [12] recently proposed a Bayesian decision-theoretic approach.
A recent overview paper on the topic of subgroup identification is [13]. Most of the methods men-
tioned above, however, have been developed in the context of two-arm randomized clinical trials
that compare a new treatment against a control. In this paper we focus on dose-finding trials,
where patients are administered different doses of the same treatment.
Dose-finding trials are an important part of drug development programs. Trials with multiple
active doses of the same treatment are therefore common in late-stage development, such as Phase
II dose-finding trials (see [14, 15] for an overview) but also Phase III trials.
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[16] recently proposed a subgroup identification approach for dose-finding trials, which makes
use of the model-based recursive partitioning algorithm [17]. This approach identifies subgroups
of patients based on parameter instabilities in Emax models, which are commonly used to model
dose-response relationships [14, 18]. This approach shares the general advantages of recursive
partitioning methods, namely ability to deal with higher-order interactions, as well as good inter-
pretability. However dose-response modeling is performed separately in each identified subgroup
without borrowing information between subgroups and thus covariates used for splitting affect all
dose-response parameters at the same time.
In this paper we propose an alternative Bayesian approach to identify relevant predictive co-
variates in dose-response trials. Our approach uses Bayesian hierarchical non-linear dose-response
models with dose-response parameters depending on covariates. We make use of shrinkage priors,
that support sparse solutions. These priors are used to represent the common baseline assumption,
that many covariates are assumed to have negligible effects on treatment effects and that strong
treatment effect heterogeneity is the exception rather than the norm. Such priors also help to
prevent overfitting in the considered setting, where commonly many covariates are investigated
and sample sizes are quite small.
We consider three priors: the spike-and-slab ([19, 20]), the horseshoe [21] and the regularized
horseshoe [22]. The spike-and-slab is a two-component discrete mixture prior and is often consid-
ered the gold standard for Bayesian variable selection. The horseshoe is a continuous shrinkage
prior, which can be considered an alternative to the spike-and-slab and has shown similar or better
performance in a number of scenarios [21, 23]. The regularized horseshoe is a recently proposed
modified version of the horseshoe, which solves MCMC convergence issues occurring for the original
horseshoe, when sampling from the posterior.
In this paper we also investigate different ways to model the relationship between prognostic
and predictive effects. While predictive covariates are of main interest for uncovering treatment
effect heterogeneity, prognostic covariates have to be taken into consideration as well, since they
can help explaining part of the variability in clinical response. Priors on prognostic and predictive
effects of the same covariates can be modeled independently. However there are arguments, which
could be made for modeling prognostic and predictive effects of covariates dependently. First, from
a modeling perspective, increasing the probability of prognostic and predictive effects occuring
together, helps to clearly distinguish prognostic and predictive effects and avoids possible bias in
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the size of the predictive effect. In addition, from a biological perspective, a covariate, which has
already been identified as predictive, could be considered more likely to be prognostic as well and
vice versa.
The prognostic and predictive effects in our setting are similar to the concept of main effects
and interactions in standard linear models. Dependent variable selection for main effects and inter-
actions has been discussed in [24] for discrete-mixture priors and in [25] for continuous shrinkage
priors. The above papers introduce hierarchies between main effects and interactions and reduce
the chance of including an interaction without the main effect, which reduces the prior probabilities
for selecting interactions. Here we propose an alternative solution, that is tailored to investiga-
tions of treatment effect heterogeneity, where the focus lies on identifying predictive covariates, e.g.
interaction. Our proposed prior distributions increase the probability of including the prognostic
effect of a covariate, when the covariate is identified as predictive, while the marginal priors for
predictive covariates are unaffected.
The paper is structured as follows: In the next section we will introduce a motivating example
based on a Phase II dose-finding study. In Section 3 we will introduce our Bayesian approach,
starting with the models used and then discussing the considered shrinkage priors, as well as our
proposed solutions for modeling dependencies between prognostic and predictive effects and the
identification of subgroups. Section 4 contains a simulation study evaluating the properties of
the proposed method and comparing different shrinkage priors. In Section 5 the example will
be revisited and analysed to illustrate the methodology. Conclusions and some discussion are
presented in Section 6.
2 A motivating example
In Phase II analyses are performed to identify whether any, and if so, which baseline covariates
modify the treatment effect. The result of these analyses can be used to inform decisions for the
design of subsequent clinical trials.
As an example we consider data from a dose-finding trial conducted to assess the efficacy of
a new treatment for an inflammatory disease. For reasons of confidentiality all variable names
are non-descriptive and all continuous variables have been rescaled to have mean 0 and standard
deviation 1. We have complete data from 270 patients, which were randomized to different dose
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groups, receiving either a placebo (n = 75) or the new drug at dose levels 25 (n = 54), 50 (n = 62)
and 100 (n = 79). The primary endpoint is the change from baseline in a continuous variable.
Additionally baseline measurements of 10 covariates – 6 of which are categorical and 4 of which
are continuous – are available for each patient.
The mean responses at the dose levels in the trials along with the confidence intervals are
shown in Figure 1, which suggest a clear dose-response effect. Still there is interest in further
investigation for possible predictive covariates or a subgroup with differential treatment effect. In
the next section we will develop a methodology for modelling the dose-response curve, but allowing
for covariates to affect dose-response parameters, based on shrinkage priors. We will return to this
example in Section 5.
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Figure 1: Mean responses and 90%-confidence intervals for the dose-finding trial example.
3 Methodology
We consider the situation of a clinical trial with n patients, that receive doses d1, ..., dn of a new
treatment at l dose levels, so that di ∈ {d˜1, ..., d˜l}, where the lowest level is a placebo, d˜1 = 0. In
addition we observe outcomes y1, ..., yn.
A commonly used model for dose-response relationships is the Emax model, which can fit a
variety of monotonous shapes. It has been shown to be adequate in a wide variety of real dose-
response situations [18] and is non-linear in its parameters. For the case of normally distributed
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responses we can write the model as
yi ∼ N(µi, σ2), for i = 1, . . . , n
µi = E0 + Emax
dh
dh + EDh50
,
(1)
where E0 can be interpreted as the mean response under placebo (d = 0), Emax is the maximum
treatment effect as the dose goes to infinity, ED50 is the dose, where a treatment effect of 0.5Emax
is reached and h influences the steepness of the dose-response curve around ED50.
For many clinical trials additional baseline covariates x
(1)
i , . . . , x
(k)
i , are measured for each pa-
tient, examples are the baseline value of the outcome variable, clinical covariates characterizing
disease severity, demographical covariates or biomarkers. The covariates are often prespecified for
possible investigation of treatment effect heterogeneity based on clinical knowledge as well as phar-
macological understanding of the drug. Exploratory analyses are then performed after the trial
has ended to detect possible predictive covariates, which modify the treatment effect, and identify
subgroups defined by these predictive covariates. For the dose-response situation one can include
linear covariates on the dose-response model parameters in (1), to detect relevant prognostic and
predictive covariates.
We propose to use shrinkage and variable selection priors on the effects of covariates to protect
against overfitting in these settings. As is common in the context of variable selection and penalized
regression we assume, that the covariates have been centered and scaled to have mean 0 and
standard deviation of 1. In the remainder of this Section we will generally assume, that our
covariates are continuous. We discuss a possible way of dealing with categorical covariates, when
we analyze the example trial in Section 5.
3.1 Model specification
In the context of subgroup analyses we are interested in identifying covariates, which have an
effect of parameters of the dose-response model and thus influence the placebo response E0 and
the treatment effect curves of patients Emaxd
h/(dh + ED50h). For the dose-response parameters
we assume
E0 = αE0 + β1x
(1) + · · ·+ βkx(k)
Emax = αEmax + γ1x
(1) + · · ·+ γkx(k)
log(ED50) = αED50 + δ1x
(1) + · · ·+ δkx(k).
(2)
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We assume here, that there is only limited prior knowledge about the dose-response shape and
standard deviation σ. We thus choose weakly informative, flat priors for αE0 , αEmax and σ and
functional uniform priors for the non-linear parameters αED50 and h. These priors are specified in
appendix A. We call the null model, a model, where β = γ = δ = 0. The null model assumes the
same parameters of the Emax model (1) for all patients. This is similar to the model, that would be
routinely fit, when a dose-response analysis is conducted in a clinical trial, which typically however
adjusts for known prognostic factors on E0 as well.
3.2 Shrinkage priors
For the parameters β, γ and δ, we could specify non-informative or weakly informative priors,
but this will lead to overfitting, since the number of covariates can often grow quite large in the
considered settings [13]. Thus it is more reasonable to choose a shrinkage prior, which better reflects
our prior beliefs of small or negligible effects for most covariates, as discussed in the Introduction.
3.2.1 Spike-and-slab
The spike-and-slab prior is often considered to be the ”gold-standard” for Bayesian variable selec-
tion [19, 20]. This prior assumes mixture distributions for the coefficients, where the first component
of the mixture is a narrow spike around zero the and the second, the ”slab”, is usually a wider
normal distribution. The spike-and-slab priors we use in this paper have the form
θ ∼ λ ·N(0, c2) + (1− λ) · δ(0)
λ ∼ Bern(p),
where δ(0) is the Dirac-measure at 0, producing the spike and c is the width of the slab. The priors
we will use in this article, writing the priors in terms of a mixture over the variance, are
βj ∼ N(0, c2βλ(prog)j
2
), j = 1, . . . , k
γj ∼ N(0, c2γλ(pred)j
2
), j = 1, . . . , k
δj ∼ N(0, c2δλ(pred)j
2
), j = 1, . . . , k
(3)
with
λ
(prog)
j ∼ Bern(φ), j = 1, . . . , k
λ
(pred)
j ∼ Bern(φ), j = 1, . . . , k.
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and priors on the slab width
cβ ∼ InvGamma(0.5, 0.5)
cγ ∼ InvGamma(0.5, 0.5)
cδ ∼ InvGamma(0.5, 0.5).
With the prior specified as above a covariate can only have a non-zero effect on both Emax and
ED50 at the same time, which is plausible as both parameters affect the treatment effect curve.
In addition it was shown that parameters acting on ED50 alone are hard to identify reliably [27],
which is why we opt for this less complex prior.
The spike-and-slab prior prior is attractive in our setting, since we can easily identify the
important covariates based on the posterior distribution of the λj and obtain posterior probabilities,
that the effects of certain covariates will be non-zero. We can incorporate further prior information
through the choice of the inclusion probabilities φ, which is discussed in more detail in Section
3.4.1.
3.2.2 Horseshoe
The horseshoe prior [21] is a shrinkage prior, belonging to the class of so-called global-local shrinkage
priors. For priors in these class the variance of the coefficients is a mixture of a global and
local component. While the global component allows shrinking spurious effects to zero, the local
component allows strong signals to persist. This makes it preferable to other shrinkage priors,
which can sometimes overshrink strong signals [21]. This is an attractive property in the setting
we consider, since we expect many covariates to have no effects, however we don’t want to miss
strong signals of truly predictive covariates.
Unlike the spike-and-slab, which shrinks coefficients either completely to zero or induces shrink-
age through a normal distribution with the same variance for all coefficients, the horseshoe also
allows for continuous shrinkage between these two extremes. The horseshoe has shown similar or
better variable selection performance than the spike-and-slab and outperforms other continuous
shrinkage priors in many settings [21, 23], making it a good default continuous shrinkage prior.
Using horseshoe priors for the coefficients in the dose-response scenario results in the following
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prior distributions
βj ∼ N(0, τ 2βλ(prog)j
2
), j = 1, . . . , k
γj ∼ N(0, τ 2γλ(pred)j
2
), j = 1, . . . , k
δj ∼ N(0, τ 2δ λ(pred)j
2
), j = 1, . . . , k.
(4)
As mentioned above the prior variance of the coefficients is a mixture of a local component for
that specific coefficient and a global component, which is in our setting different between covariate
effects on E0, ED50 and Emax. The prior distributions for the local components are chosen as
positively bounded Cauchy- distributions,
λ
(prog)
j ∼ C+(0, 1), j = 1, . . . , k
λ
(pred)
j ∼ C+(0, 1), j = 1, . . . , k,
whereas the global components have distributions
τβ ∼ C+(0, η2β)
τγ ∼ C+(0, η2γ)
τδ ∼ C+(0, η2δ ).
As for the spike-and-slab, local shrinkage for effects on ED50 and Emax is equal to reduce the
number of parameters. Possible choices for the scale of the global shrinkage parameters ηβ, ηγ and
ηδ will be discussed in Section 3.4.1.
3.2.3 Regularized horseshoe
While the horseshoe has many attractive theoretical properties, it is susceptible to convergence
issues in practice, when using sampling methods to draw from posterior distributions like Stan
[26]. These issues have been discussed in [27] and we noticed these problems with the horseshoe as
well.
To solve convergence issues, in [22] an extension of the horseshoe called the regularized horseshoe
was proposed. The regularized horseshoe prior for the coefficients in the dose-response model
replaces the λ
(prog)
j in (4) with
λ˜
(prog)
j =
√√√√√ c2βλ(prog)j 2
c2β + τ
2
βλ
(prog)
j
2 , j = 1, . . . , k, (5)
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where λ
(prog)
j ∼ C+(0, 1) as before. Similarly the local shrinkage components for the predictive
coefficients are replaced. When there is a lot of shrinkage, τ 2βλ
2
j << c
2
β and λ˜
2
j will be close to
λ2j . When there is only little shrinkage on the other hand the distribution of βj will be close to
N(0, c2β). Thus the regularized horseshoe introduces some additional shrinkage for large effects,
where the amount of shrinkage is determined by cβ (for prognostic effects) and by cγ and cδ (for
predictive effects). We choose prior distribution for cβ (and same for cγ and cδ), following [22],
cβ ∼ InvGamma(2, 2).
3.3 Dependencies between prognostic and predictive effects
The priors discussed above treat prognostic and predictive effects as independent. Instead we
could consider priors, which introduce dependencies between prognostic and predictive effects of
covariates. In this section we propose variants of the spike-and-slab and the horseshoe priors, which
make it unlikely to include covariates as only predictive and instead favor covariates, to be both
prognostic and predictive. As discussed in the Introduction, there are two main arguments for
using dependent priors over independent priors.
Firstly, by including the prognostic (main) effect, when the predictive (interaction) effect is
included, prognostic and predictive effects can be distinguished more clearly and the of falsely
identifying a prognostic effect as predictive can be reduced.
Secondly, a prior with dependencies might be more plausible from a a clinical perspective. A
covariate, that is predictive and therefore interacts with the treatment’s mechanism of action in
some way, might be deemed more likely to affect the clinical response in general and therefore be
prognostic as well. While there are certainly covariates or biomarkers, that are only predictive one
might argue that the prior probability for a covariate to be prognostic should be increased, when
it is already identified as predictive.
On the other hand, we don’t want to inflate the probability to identify predictive covariates and
with it the number of false positive identifications. Thus the marginal prior probability to identify
a covariate as predictive should be same as if we were using independent priors. We can condense
the above consideration into two probability statements,
P (xj is prognostic|xj is predictive) > P (xj is prognostic|xj is not predictive)
P (xj is predictive) = pind,
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where pind is the prior probability to include xj as predictive if we would use independent priors. In
the following we propose prior distributions for prognostic and predictive effects, which represent
these prior beliefs.
We can achieve this for the spike-and-slab by using a modified prior on the inclusion variables
in (3),
λ
(pred)
j ∼ Bern(φ), j = 1, . . . , k.
λ
(prog)
j |λ(pred)j ∼ Bern(φ∗), j = 1, . . . , k
φ∗ =
φinc if λ
(pred)
j = 1
φ if λ
(pred)
j = 0,
(6)
where φ < φinc ≤ 1, so the inclusion probability for prognostic effects is increased, if the predictive
effect is in the model. The choice of φinc determines how much more likely a covariate is prog-
nostic and predictive versus only predictive. The resulting marginal prior distribution of λ
(prog)
j is
Bern(φ · (1 − φ + φinc)), while the marginal distribution for λ(pred)j is Bern(φ), the same as with
the independent priors in Section 3.2.1. In the remainder of this article we use φinc = 0.8, so that
P (λ
(prog)
j = 1|λ(pred)j = 1) = 4 · P (λ(prog)j = 1|λ(pred)j = 0).
Similarly, for the local shrinkage components of the horseshoe in (4) we propose the priors
λ
(∗)
j ∼ C+(0, 1), j = 1, . . . , k
λ
(pred)
j ∼ C+(0, 1), j = 1, . . . , k
λ
(prog)
j = max(λ
(∗)
j , λ
(pred)
j ), j = 1, . . . , k,
(7)
which don’t allow to shrink the prognostic effects more than predictive effects. For the regularized
horseshoe the same idea is used for λ˜j.
3.4 Practical considerations
3.4.1 Choice of hyperparameters
All shrinkage priors above include hyperparameters, which should be chosen in accordance with
prior information. For the spike-and-slab prior the inclusion probabilities φ has to be specified. To
control for multiplicity in our setting the inclusion probabilities can be lowered, when the number
of considered covariates is increased, to keep the expected number of non-zero effects constant. For
example a choice of φ = 0.2 leads to 0.2 · k covariates with non-zero effects a priori.
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For the horseshoe and the regularized horseshoe the scale of the global shrinkage parameter
has to be specified. Originally scales of η = 1 or η = σ were proposed for the global shrinkage
components of the horseshoe. However [22] recently showed, that these fixed choices can result in
a large number of non-zero effects a priori, especially if k is large. Instead they propose choosing
the global components’ scale dependent on the problem.
In our setting we have to specify the scales ηβ, ηγ and ηδ. These global shrinkage parameters
play a similar role as the inclusion probability φ for the spike-and-slab, in that they determine the
number of non-zero coefficients expected a priori. A possible approach to find the scales for the
global shrinkage component is to use the spike-and-slab as a benchmark. By drawing samples from
the prior distribution for the horseshoe with different global scale parameters and comparing them
to the spike-and-slab with the desired inclusion probabilities we can obtain a horseshoe prior, which
contains similar prior information. In principle the whole prior distribution could be compared. In
this article we will generally try to match two prior probabilities for each set of coefficients (β, γ
and δ). The first probability represents the behavior of the prior close to zero, while the second
represents the prior behavior away from zero. We try to minimize
g(η) = (P (θHS < qsmall|η)− P (θSaS,φ < qsmall))2 + (P (θHS < qlarge|η)− P (θSaS,φ < qlarge))2 (8)
with regard to η, where θHS follows a horseshoe prior distribution, θSaS,φ and has a spike-and-slab
prior with inclusion probability φ. qsmall defines an interval around zero, in which any effects are
considered to be negligible for the problem at hand. On the other hand values, that are bigger
than qlarge are considered to be large effects. For example given some guesstimate for Emax, Emax
∗,
reasonable values could be qsmall = 0.1 ·Emax∗ and qlarge = 1 ·Emax∗. Values for E0 and ED50 could
be derived similarly.
Global scale parameters for the regularized horseshoe can be obtained with the same approach.
3.4.2 Identifying subgroups
The Bayesian modeling approach discussed above does not directly identify subgroups of patients
with enhanced treatment effects. In this Section we will outline some strategies to identify a
subgroup of patients using the output of our model.
The Bayesian framework we are using allows us to make probability statements about individual
patients’ dose-response parameters and treatment effects. We can therefore define a subgroup of
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patients by using the available posterior distributions. Say for example, that we are interested in
identifying a subgroup of patients with a predicted treatment effect at a specific dose (for example
the highest dose in the trial) above a certain threshold ψ. With our model we can estimate the
treatment effects for patient i as a function of the covariates and the dose as
∆i(xi, d) = (αEmax + x
′
iγ)
dh
dh + [exp(αED50 + x
′
iδ)]
h
. (9)
We can then use the posterior distribution P (∆i(xi, d)|y) of these treatment effect estimates to
define a subgroup with an increased response as
S = {i ∈ {1, . . . , n}|P (∆i(xi, d) > ψ|y) > ω}, (10)
where ω ∈ [0.5, 1] reflects the posterior probability for a treatment effect larger than ψ, that is
required to place a patient in the subgroup. For example for ω = 0.5 all patients with posterior
median treatment effect above ψ are placed in the subgroup.
With the criterion above, the subgroup is chosen based on the whole covariate vector x. In
many situations it may be necessary to come up with an easier subgroup description, which only
depends on a small number of covariates and is more interpretable for clinicians and patients. If
only a small number of covariates is identified as predictive, a subgroup could be defined using
those covariates. For continuous covariates a suitable cut-off has to be found.
Alternatively, a regression tree could be fit, using the posterior mean (or median) treatment
effects at the highest dose or the posterior median Emax as the outcome and the covariates as
predictors. The regression tree would then identify subgroups with different treatment effects. A
similar approach for two-arm trials is proposed in [4].
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Choose prior for covariate effects
Choose an inclusion probability, for example φ = 0.2k
Choose dose-response parameter
guesstimates based on clinical knowl-
edge, previous trials, primary analysis
Determine what would be large and what
would be negligible effects (qlarge and qsmall)
Scales for global
shrinkage parameters
Uninformative pri-
ors for remaining
model parameters
Bayesian
dose-response
model
Individual treat-
ment effect curves
Predictive covariates
Individual dose-
response parameters
Subgroup identification
horseshoe/reg. horseshoe
spike-and-slab
minimize (8)
Figure 2: Overview over proposed procedure to identify subgroups using Bayesian hierarchical
dose-response models
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4 Simulation study
In this Section we will evaluate the performance of our method using the several shrinkage priors we
discussed in Section 3 using simulated dose-response trials. The scenarios we consider are similar
to the ones in [16], but here we generally assume, that covariate effects are linear. Some additional
scenarios with non-linear functions of covariates and interactions between covariates are discussed
in Section 4.4. We simulate clinical trials with n = 500 (n = 250) patients, which are equally
distributed across 5 dose groups with dose levels 0, 12.5, 25, 50, 100. We generate a vector of k
baseline covariates for each patient i as xi ∼ N(0, Ik). We consider two possible values for the
number of covariates k, 10 and 30.
We generate normally distributed responses from an Emax model with h = 1,
yi ∼ N(µi, 0.252) i.i.d,
µi = E0(xi) + Emax(xi)
di
ED50(xi) + di
for i=1,...n,
(11)
with different scenarios for covariate effects on dose-response parameters, which are summarized
in Table 1. In the first two scenarios there are no predictive covariates and all patients have
the same treatment effect curve. In the third and fourth scenario there are predictive covariates,
and as a result heterogeneous treatment effect curves for the patients. In scenario 3 and 4 80%
of patients have Emax between 0 and 0.34, so that there are only small groups of patients with
negative treatment effects or more than double of the average treatment effect. For the ED50 80%
of patients lie between 5 and 80.
For these simulated trials we fit hierarchical dose-response models as discussed in Section 3
using different types of shrinkage priors. We also include some models without shrinkage priors for
comparison. These include a null model, which assumes constant dose-response parameters for all
Table 1: Covariate effect scenarios for the simulated dose-response studies.
Scenario E0(x) Emax(x) ED50(x)
1 (null) 1.2 0.17 20
2 (only prognostic) 1.2 + 0.1x(1) + 0.1x(2) + 0.05x(3) 0.17 20
3 (prognostic and predictive) 1.2 + 0.1x(1) + 0.1x(2) + 0.05x(3) 0.17 + 0.1x(2) − 0.1x(3) 20exp(−0.75x(2) + 0.75x(3))
4 (only predictive) 1.2 0.17 + 0.1x(2) − 0.1x(3) 20exp(−0.75x(2) + 0.75x(3))
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Table 2: Overview over different types of Bayesian dose-response models compared in the simulation
study.
Abbreviation Method
null model without covariate effects
noshrink model with flat priors
oracle model with true covariate effects
hs model with independent horseshoe shrinkage priors
hs dep model with dependent horseshoe shrinkage priors
rhs model with independent reg. horseshoe shrinkage priors
rhs dep model with dependent reg. horseshoe shrinkage priors
sas model with independent spike-and-slab priors
sas dep model with dependent spike-and-slab priors
patients without any covariate effects, a model with flat priors on the coefficients in (2) and finally
an oracle model, which always knows the correct form of the covariate effects in Table 1. For this
last model we then also use flat priors on all coefficients in the model. All considered methods are
summarized in Table 2.
For the simulations we choose φ = 2
k
as the inclusion probability for the spike-and-slab prior.
Therefore we are a priori expecting two covariates with non-zero effects, no matter how many
covariates are considered in total. For the horseshoe priors we then choose ηβ, ηγ and ηδ, which
minimize the expression (8). We use guesstimates E0
∗ = 1.2, Emax∗ = 0.17 and then follow the
suggestions in section 3.4.1, so that qsmall = 0.1E0
∗ = 0.12 and qlarge = E0∗ = 1.2 for ηβ and
qsmall = 0.1Emax
∗ = 0.017 and qlarge = Emax∗ = 0.17 for choosing ηγ. For ηδ, we don’t need any
guesstimate, since coefficients for ED50 are defined on a log-scale, and qsmall = log(1.1) = 0.1 and
qlarge = log(2) = 0.7 thus represent 10% and 100% changes from the average ED50. The resulting
hyperparameter values we choose for the horseshoe for different scenarios are summarized in Table
3.
We use the following performance metrics to compare the different methods: estimation of
individual patients’ treatment effect curves, correct selection of predictive covariates and identifi-
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Table 3: Scales used for the global shrinkage parameter of the horseshoe and the regularized
horseshoe for the simulation study.
parameter k = 10 k = 30
ηβ 0.030 0.006
ηγ 0.006 0.001
ηδ 0.026 0.005
cation of subgroups with increased treatment effects. In addition, in Subsection 4.4 we compare
the performance of the Bayesian approaches presented here to model-based recursive partitioning
considering also non-linear functions of the covariates on the dose-response parameters. The results
depicted in the main part of this article focus on the scenario with n = 500 and k = 10. Results
for other considered scenarios are similar and can be found in the Supplementary Material.
Simulations were performed using R [28]. For the models with Spike-and-Slab priors JAGS [29]
was used for sampling, for all other models we used Stan [26].
4.1 Estimation of individual treatment effect curves
With the Bayesian models we consider here we can predict an individual treatment effect curve for
every patient. In this section we compare the different models in Table 2 we consider with regard
to the accuracy of their predictions. For each patient we use the posterior mean of the treatment
effect as estimated in (9) at the 4 active doses in the simulated trials and then take the average
of the root mean squared error (RMSE) over these doses and over the patients. The distribution
of this metric over 1000 simulated clinical trials is visualized for the different Bayesian modeling
approaches in Figure 3.
For the null - and the only prognostic- scenarios all patients have the same true treatment effect
curves. The shrinkage priors we consider all show the desired behaviour of shrinking all coefficients
here to zero and the resulting predictions have similar accuracy as the oracle or the null models,
which both assume the treatment effect is the same for all patients in these two scenarios. The
difference between the shrinkage priors with and without dependence is negligible in these two
scenarios. Only the model that assumes flat priors on the covariates performs bad here, which
17
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Figure 3: Distribution of RMSE over 1000 simulated trials for treatment effect predictions averaged
over patients and doses with n = 500 (100 patients per group) and k = 10 covariates.
shows that this approach is prone to overfitting.
In the remaining scenarios with predictive effects differences between the shrinkage priors are
more visible. In scenario 3 with prognostic and predictive effects the dependent priors (hs dep,
rhs dep and sas dep) clearly improve the estimation of treatment effect curves compared to the
independent variants (hs, rhs, sas). Also the horseshoes priors show better performance than the
spike-and-slab. In the final scenario with only predictive effects the independent priors perform
slightly better, as would be expected, since the dependent priors give this scenario lower prior
probability. Still, the difference to the dependent priors is quite small.
4.2 Identification of predictive covariates
Identifying predictive covariates is a key aspect of subgroup identification. To determine, which
covariates have effects on the dose-response parameters, we use the 50% highest posterior density
credible intervals for the covariate effects (β, γ and δ) and assume that covariates have an effect,
if zero is not included in the credible interval. This criterion was suggested for Bayesian variable
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selection in [30].
Results for the variable selection performance with different shrinkage priors are summarized
in Table 4 for the 4 considered scenarios. In the first two scenarios all shrinkage priors correctly
determine in almost all cases, that no covariates should be selected as predictive. Covariates, that
are only prognostic are slightly more often selected in the second scenario. The dependent priors
seem to slightly reduce the selection of prognostic covariates as predictive.
In the scenario with both prognostic and predictive effects, the dependent shrinkage priors
work much better than the independent shrinkage priors and increase the selection of all correct
covariates with no visible increase in wrong selections. In the last scenario with only predictive
effects the dependent priors are sometimes slightly worse than the independent priors, however
the selection probabilities are quite similar. Interestingly the horseshoe priors seem to be better
at identifying predictive covariates on Emax, while the spike-and-slab seems better at identifying
covariates on ED50.
4.3 Subgroup identification
In the previous Section we have only considered the identification of single predictive covariates.
However we can also consider the identification of a subgroup with an increased treatment effect.
To identify a subgroup with an increased treatment effect we use one of the methods discussed in
(3.4.2) and estimate a subgroup of patients with increased treatment effects as in (10) with ψ = 0.2
and ω = 0.5, so that all patients with posterior median treatment effects above 0.2 at the highest
dose are in the subgroup. We can then compare this estimated subgroup Sˆ to the true subgroup of
patients with such an increased effect, S. We can compare the similarity of the estimated subgroup
to the true subgroup using sensitivity (|Sˆ∩S|/|S|), specificity (|SˆC ∩SC |/|SC |), positive predictive
value (|Sˆ ∩ S|/|Sˆ|) and negative predictive value (|SˆC ∩ SC |/|SˆC |). Additionally we track the size
of S and Sˆ, and if Sˆ is non-null, e.g. Sˆ 6= ∅. The average of these metrics over 1000 simulated
clinical trials is summarized in Table 8 in appendix B.
In the first and second scenario scenario there is no subgroup with an increased treatment effect.
With shrinkage priors we still identify a subgroup 10% of the time for the horseshoe and in 4% for
the spike-and-slab. However these subgroups generally are small and specificity therefore is high
at 97%. In the second scenario the presence of prognostic covariates seems to lead to a subgroup
being identified slightly more often. In scenario 3 with prognostic and predictive effects sensitivity
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is higher for the horseshoe priors than for the spike-and- slab, while specificity is essentially the
same between methods. The dependent priors are slightly more sensitive than independent priors.
In the last scenario the independent spike-and-slab seems to perform best with regard to subgroup
identification, however all shrinkage priors show very similar performance in that scenario.
20
Table 4: Rel. frequency of covariates being selected as having effects on E0, Emax and ED50 with
n = 500 (100 per group) and k = 10 covariates.
E0 ED50 Emax
scenario method x1 x2 x3 x4 x1 x2 x3 x4 x1 x2 x3 x4
null oracle 0 0 0 0 0 0 0 0 0 0 0 0
noshrink 0.55 0.51 0.58 0.54 0.53 0.53 0.54 0.51 0.46 0.44 0.45 0.45
hs 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
hs con 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
rhs 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
rhs dep 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
sas 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
sas dep 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
only progn. oracle 1 1 1 0 0 0 0 0 0 0 0 0
noshrink 1.00 1.00 0.95 0.56 0.52 0.52 0.54 0.55 0.46 0.49 0.46 0.47
hs 0.99 1.00 0.94 0.02 0.01 0.00 0.00 0.00 0.00 0.00 0.01 0.00
hs dep 1.00 1.00 0.99 0.09 0.01 0.00 0.00 0.00 0.01 0.01 0.00 0.00
rhs 0.99 1.00 0.93 0.02 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.00
rhs dep 1.00 1.00 0.99 0.10 0.01 0.00 0.00 0.00 0.00 0.01 0.00 0.00
sas 0.98 0.99 0.71 0.00 0.01 0.01 0.03 0.00 0.02 0.01 0.05 0.00
sas dep 0.99 1.00 0.80 0.00 0.01 0.00 0.01 0.00 0.01 0.01 0.01 0.00
progn. & pred. oracle 1 1 1 0 0 1 1 0 0 1 1 0
noshrink 1.00 1.00 0.86 0.54 0.53 0.90 0.89 0.56 0.49 0.96 0.96 0.50
hs 0.99 0.96 0.14 0.02 0.00 0.18 0.08 0.00 0.01 0.55 0.31 0.00
hs dep 1.00 1.00 0.32 0.03 0.01 0.24 0.10 0.00 0.02 0.75 0.34 0.00
rhs 0.99 0.95 0.14 0.01 0.00 0.19 0.09 0.00 0.01 0.55 0.29 0.00
rhs dep 1.00 1.00 0.31 0.02 0.01 0.25 0.11 0.00 0.01 0.77 0.33 0.00
sas 0.99 0.84 0.09 0.00 0.01 0.29 0.16 0.00 0.01 0.45 0.23 0.00
sas dep 0.99 0.96 0.18 0.00 0.00 0.39 0.19 0.00 0.01 0.59 0.28 0.00
only pred. oracle 0 0 0 0 0 1 1 0 0 1 1 0
noshrink 0.52 0.63 0.64 0.56 0.54 0.91 0.89 0.55 0.46 0.95 0.95 0.47
hs 0.00 0.03 0.03 0.00 0.00 0.29 0.30 0.00 0.00 0.91 0.90 0.00
hs dep 0.00 0.05 0.05 0.00 0.00 0.27 0.27 0.00 0.00 0.91 0.90 0.00
rhs 0.00 0.03 0.03 0.00 0.00 0.32 0.32 0.00 0.00 0.91 0.91 0.00
rhs dep 0.00 0.04 0.04 0.00 0.00 0.28 0.28 0.00 0.00 0.91 0.91 0.00
sas 0.00 0.03 0.03 0.00 0.00 0.76 0.77 0.00 0.00 0.96 0.96 0.00
sas dep 0.00 0.06 0.07 0.00 0.00 0.67 0.69 0.00 0.00 0.91 0.89 0.00
Italic numbers indicate true prognostic covariates, bold numbers indicate true predictive covariates.
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4.4 Comparison to model-based recursive partitioning
Model-based recursive partitioning (mob) has been proposed in [16] for subgroup identification in
dose-finding trials. It is of interest to investigate how the Bayesian approaches we consider here,
compare to this conceptually different approach. Recursive partitioning methods are well known for
their ability to handle interactions as well as non-linearity. In the simulation scenarios discussed
above, depicted in Table 1, we assumed, that dose-response parameters are linear functions of
the covariates. Here, to assess the robustness of the Bayesian approach described in this article,
which always assumes linearity, in comparison to the more flexible recursive partitioning approach,
we will also consider scenarios with non-linear functions of the covariates. Apart from linear
covariate effects as above, we additionally consider scenarios with step functions, logistic functions
and interactions between covariates. We consider these different functional forms in a scenario
with prognostic and predictive effects (similar to scenario 3 in Table 1). The different types of
covariate effects considered here are summarized in Table 5. As in the previous Sections we compare
estimation of individual treatment effect curves, selection frequency of covariates as predictive
(either on Emax or ED50) and subgroup identification metrics for the different Bayesian shrinkage
priors and the mob approach. For mob we use the same settings as proposed in [16], e.g. a minimum
node size of 20, significance level alpha of 0.1 and Bonferroni adjustments for multiplicity. In
addition we restrict the partitioning to covariate effects on ED50 and Emax, since we are mostly
interested in identifying predictive covariates.
The results for treatment effect curve estimation are depicted in Figure 5 in Appendix B. As
expected mob shows similar or better performance than the Bayesian approaches for the step-
function and interaction scenario, for which tree approaches should be particularly well suited. It
is worth noting, however, that the null model shows the best performance (apart from the oracle)
in the interaction scenario. The interaction scenario seems to be the most difficult scenario for all
methods, there is also no big difference between the noshrink model and the models with shrink-
age priors. In the other scenarios the approaches using shrinkage priors all still work reasonably
well and generally beat noshrink - and null -models. Simulation results for selection frequency of
covariates as predictive are summarized in Table 6. When using mob we consider a covariate to
be selected as predictive, if it is at any point used for a split in the tree. Mob generally seems to
select more covariates (right or wrong ones) than the Bayesian approaches with shrinkage priors.
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Table 5: Covariate effect scenarios for the simulated dose-response studies in Subsection 4.4.
functional form E0 Emax
linear 1.2 + 0.1x(1) + 0.1x(2) + 0.05x(3) 0.17 + 0.1x(1) − 0.1x(3)
logistic 0.7 + 0.4L(x(1)) + 0.4L(x(2)) + 0.2L(x(3)) 0.17 + 0.34L(x(1))− 0.34L(x(3))
step-function 1.2 + 0.1I(x(1)) + 0.1I(x(2)) + 0.05I(x(3)) 0.17 + 0.1I(x(1))− 0.1I(x(3))
linear with interaction 1.2 + 0.1x(1) + 0.1x(2) + 0.05x(3) + 0.2x(1)x(2) 0.17 + 0.1x(1) − 0.1x(3) + 0.2x(2)x(3)
ED50
linear 20 · exp(−0.75x(2) + 0.75x(3))
logistic 20 · exp(−2L(x(2)) + 2L(x(3))
step-function 20 · exp(−0.75I(x(2)) + 0.75I(x(3)))
linear with interaction 20 · exp(−0.75x(2) + 0.75x(3) − x(2)x(3))
L(z) := 1/(1 + exp(−2z)) and I(z) := I(z > 0).
Table 6: Rel. frequency of covariates being selected as predictive (either on ED50 or on Emax)
with n = 500 (100 per group) and k = 10 covariates for different functional forms in scenarios with
prognostic and predictive covariates.
linear interaction logistic step-function
method x1 x2 x3 x4 x1 x2 x3 x4 x1 x2 x3 x4 x1 x2 x3 x4
oracle 0 1 1 0 0 1 1 0 0 1 1 0 0 1 1 0
noshrink 0.75 0.98 0.99 0.76 1.00 1.00 1.00 0.71 0.76 0.90 0.89 0.71 0.71 0.84 0.83 0.72
hs 0.01 0.56 0.32 0.01 1.00 1.00 0.98 0.01 0.03 0.33 0.03 0.00 0.02 0.52 0.01 0.01
hs dep 0.03 0.77 0.35 0.00 1.00 1.00 0.98 0.01 0.03 0.36 0.03 0.00 0.03 0.42 0.01 0.00
rhs 0.01 0.56 0.30 0.00 1.00 1.00 0.99 0.01 0.03 0.32 0.04 0.00 0.02 0.41 0.01 0.01
rhs dep 0.02 0.79 0.35 0.00 1.00 1.00 0.99 0.01 0.03 0.35 0.04 0.00 0.03 0.33 0.01 0.00
sas 0.01 0.46 0.24 0.00 0.98 0.98 0.95 0.00 0.08 0.41 0.04 0.00 0.06 0.56 0.01 0.00
sas dep 0.01 0.60 0.28 0.00 1.00 1.00 0.96 0.00 0.03 0.32 0.02 0.00 0.02 0.41 0.00 0.00
mob 0.23 0.96 0.30 0.10 0.32 0.77 0.54 0.11 0.14 0.87 0.15 0.08 0.08 0.65 0.10 0.05
Italic numbers indicate true prognostic covariates, bold numbers indicate true predictive covariates.
The only exception seems to be the scenario with interactions, where the Bayesian approaches
essentially always select the correct predictive covariates, but also the first covariate, which is only
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prognostic. In the interaction scenario mob also identifies this covariate more often, however the
rate of identification is much lower than for the Bayesian approaches. Overall it seems that mob
is more robust with regard to possible functional forms as the results seem quite similar for all
considered scenarios. The Bayesian approaches work better than mob in the linear scenario, how-
ever they miss more predictive covariates in the logistic and step-function scenarios and seem to
be unable to distinguish prognostic and predictive effects in the interaction scenario.
The subgroup identification performance is summarized in Table 9 in appendix C. Mob generally
identifies larger subgroups and has similar or better sensitivity than the Bayesian approaches. On
the other hand the specificity of mob is generally lower.
5 Analysis of the example trial
We now come back to our example trial and use the shrinkage approach discussed above on this
dataset. As discussed in Section 2 we have 10 covariates in total, which we consider here as possible
predictive covariates. 6 of the covariates in this dataset are categorical. Dealing with categorical
covariates introduces an additional challenge in the context of variable selection. Dummy-coding is
commonly used for categorical covariates, therefore for a covariate with Z categories we introduce
Z − 1 dummy variables. In our model these dummy variables are then considered to be separate
binary covariates, however it does not make sense to shrink them completely independently, since
we want to shrink the effects of the underlying covariates, not of the dummy variables used for
coding. We therefore use the same local shrinkage components for all dummy variables belonging
to the same covariate.
To get an overall impression of the data without covariate effects, we fit a non-Bayesian sigmoid
Emax model to the data assuming no covariate effects. The results confirm the relatively clear
dose-response trend from the visual inspection of the data. We obtain ML-estimates E0 = −0.65,
Emax = 1.04, ED50 = 30.90 and h = 2.27.
For the exploratory analysis for possible predictive covariate effects and subgroups we only
consider the dependent regularized horseshoe, since this prior seemed to show good performance in
the simulation study in the previous Section. As discussed in Section 3.2.2, we have to specify the
scale for the global shrinkage component. We can use the ML-estimates above and as in Section 4
consider 10% changes and 100% changes in the dose-response parameters as small and large effects.
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Figure 4: Individual predicted dose-response curves for patients in subgroup and complement,
which is identified using either the individual Emax (A) or the predictive covariate x7 (B).
Minimizing criterion (8), we obtain global scale parameters τβ = 0.020, τγ = 0.030 and τδ = 0.039.
We then fit a a Bayesian sigmoid Emax-model as in (1) with covariate effects as in (2) using the
dependent regularized horseshoe priors.
We can get an idea of which covariates are most likely to be predictive by considering the size
of the local shrinkage coefficients λ(pred). Going by the median local shrinkage components the
most important covariates are x(7), x(9) and x(6), the first two of which are binary, while the last
is continuous. The summary statistics for the coefficients for these covariates as well as for other
important parameters of the model are given in Table 7. Looking at the coefficients for the three
important covariates, almost all of the posterior medians are close to zero. The only exception is
γ7, which describes the effect of the binary covariate x7 on Emax. The 50% credible interval for this
coefficient however still includes zero. The conclusion here seems to be, that x7 might be predictive
on Emax, however the trial at hand is likely to small to make definite conclusions. This finding
could be further investigated in another, larger trial.
Based on the above finding we would likely conclude in a real-life setting, that there is not
enough evidence for a possible subgroup. However we will continue with a possible subgroup
identification procedure based on the above models for the purposes of this example. As discussed
in Section 3.4.2 there are several options, that can be considered to define a subgroup of patients
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with a high treatment response. For example we could consider all patients with posterior median
Emax above 1.04 (the ML-estimate for the primary analysis) as a possible subgroup. Alternatively
we could consider, that x7 is a binary covariate, which has been identified as possibly predictive
and could be used to define a subgroup. Figure 4 shows the individual predicted dose-response
curves for patients in and out of the subgroups identified in these ways. The resulting subgroups
are almost identical, which further confirms, that x7 is the only important predictive covariate.
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Table 7: Posterior summaries for selected parameters of the fitted dose-response model
parameter mean sd 2.5% 25% 50% 75% 97.5%
αE0 −0.63 0.11 −0.84 −0.70 −0.63 −0.56 −0.42
αEmax 1.11 0.29 0.67 0.90 1.06 1.27 1.78
exp(αED50) 34.58 14.00 11.68 25.12 31.88 41.90 68.47
h 2.68 1.96 0.65 1.28 2.01 3.45 8.17
σ 0.91 0.04 0.83 0.88 0.91 0.93 0.99
λ
(pred)
1 1.68 6.88 0.03 0.34 0.78 1.65 8.05
λ
(pred)
2 3.98 77.21 0.03 0.35 0.84 1.79 9.79
λ
(pred)
3 0.91 1.13 0.03 0.27 0.59 1.14 3.83
λ
(pred)
4 1.58 2.80 0.03 0.35 0.82 1.73 7.75
λ
(pred)
5 1.90 6.08 0.04 0.36 0.83 1.81 10.19
λ
(pred)
6 3.35 38.47 0.04 0.41 0.99 2.24 15.47
λ
(pred)
7 8.32 64.87 0.07 0.91 2.54 6.02 39.61
λ
(pred)
8 1.56 3.25 0.03 0.35 0.78 1.65 7.49
λ
(pred)
9 3.06 15.20 0.05 0.49 1.17 2.74 14.16
λ
(pred)
10 0.89 1.10 0.03 0.26 0.58 1.13 3.63
β7 0.03 0.06 −0.04 −0.00 0.01 0.06 0.18
β9 0.02 0.04 −0.03 −0.00 0.00 0.03 0.14
β6 0.01 0.04 −0.04 −0.00 0.00 0.01 0.12
γ7 0.10 0.13 −0.03 0.00 0.04 0.17 0.43
γ9 0.02 0.07 −0.06 −0.00 0.00 0.04 0.20
γ6 −0.03 0.08 −0.29 −0.03 −0.00 0.00 0.05
δ7 0.02 0.36 −0.40 −0.03 −0.00 0.02 0.53
δ9 −0.05 0.14 −0.44 −0.04 −0.00 0.00 0.08
δ6 0.02 0.11 −0.10 −0.01 0.00 0.02 0.28
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6 Conclusions and discussion
In this paper we proposed a Bayesian approach for investigating treatment effect heterogeneity
in dose-response trials. Our approach uses shrinkage priors to take into account, that commonly
little systematic heterogeneity of treatment effects is expected. We proposed ways to incorporate
prior beliefs and control multiplicity in a Bayesian way through the hyperparameters of the prior
distributions on prognostic and predictive effect and presented ways to model dependencies between
prognostic and predictive effects of the same covariate. Our methods can deal with continuous, as
well as categorical covariates as showed in Section 5. While we focused on normally distributed
outcomes, the presented Bayesian model should be extendable to other types of outcomes as well.
Our simulation studies in Section 4 show, that the considered shrinkage priors all have the
desired behaviour of reducing the number of false positive identifications of covariates as predic-
tive. This can be seen directly in Section 4.2, where covariates, that are not predictive are almost
never selected as such. Based on the results in Section 4.1 this also results in better estimation of
individual treatment effect curves. In scenarios with predictive effects some differences were visible
between the priors with regard to the identification performance. Our results suggest, that the
horseshoe priors perform better than the spike-and-slab priors in the scenario with prognostic and
predictive effects, both with regard to variable selection and treatment effect estimation. These
properties of the priors are also reflected in the performance with regard to subgroup identification
in Section 4.3. Differences in performance between horseshoe and regularized horseshoe are negli-
gible, however we noticed the improved sampling properties for the regularized horseshoe, which
shows a much smaller number of divergences, when using Stan.
As expected priors, which model prognostic and predictive effects dependently, gave good per-
formance improvements in the scenarios with prognostic and predictive effects. Additionally the
performance in the other scenarios was similar to the independent priors. The dependent priors
therefore seemed to show the desired behaviour of improving the ability of the method to detect
predictive covariates, that are also prognostic, while only minimally increasing the rate of false
identifications for covariates, which are only prognostic. Based on our results we would therefore
recommend dependent priors over independent priors, when the main interest of the analysis is the
identification of predictive covariates.
We compared the performance of the Bayesian approaches discussed in this article to model-
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based recursive partitioning [16], a recently proposed method for identifying subgroups with hetero-
geneous treatment effects in dose-findings trials. in Section 4.4. mob showed higher rates of both
true and false positive selections in the scenarios we considered. In addition mob’s performance
was quite robust to the different functional forms we considered, whereas the performance of the
approaches presented in this article was more dependent on the functional form of the covariates,
due to assuming linearity of the covariates. However, the Bayesian models generally better estimate
individual treatment effect curves (see Figure 5 in appendix C), since they borough information
across subgroups and prefer sparse solutions. Based on our results it is hard to generally recom-
mend one method over the other, since the two approaches are conceptually different and both
have their advantages and disadvantages. In addition to the differences in operating characteris-
tics, mob also requires less input from the user and the tree output is easily interpretable, while the
Bayesian models will generally require more input from the user, but also provide a richer output
with proper statements of uncertainty for all parameters and quantities of interest.
This leads us to the limitations of the discussed approaches. Firstly we only consider linear
functions of the covariates in our models, which also do not include any covariate-covariate interac-
tions. The results of this can be seen in Section 4.4 and especially in Table 6: When the covariates
do not affect the dose-response parameters linearly the identification performance for our methods
worsens. In the scenario with interaction terms our method seems to have trouble distinguishing
prognostic and predictive covariates. However this would likely be a challenging scenario for any
method, since the prognostic covariate x1 has a (prognostic) interaction with the predictive co-
variate x2. mob also shows increased identifications of x1 as predictive in this scenario. Allowing
for more complex functional forms, for example using basis function expansions in the Bayesian
framework with shrinkage priors, could be a possibility for further research.
29
Acknowledgements
This work was supported by funding from the European Union’s Horizon 2020 research and innovation
programme under the Marie Sklodowska-Curie grant agreement No 633567 and by the Swiss State Secre-
tariat for Education, Research and Innovation (SERI) under contract number 999754557 . The opinions
expressed and arguments employed herein do not necessarily reflect the official views of the Swiss Gov-
ernment.
Appendix
A Full model specification
To complete the priors for model (2) we choose
αE0 ∼ N(0, σ2E0)
αEmax ∼ N(0, σ2Emax)
αED50 = log(ν · dmax)
h = 0.5 + 9.5 · ξ
σ ∼ InvGamma(0.01, 0.01).
Here ν and ξ are hyperparameters, while σE0 and σEmax are fixed. Since we assume limited prior knowl-
edge we would choose flat priors for E0 and Emax and choose large values for σE0 and σEmax . For the
hyperparameters we choose prior distributions
ν ∼ Beta(0.82, 3.5)
ξ ∼ Beta(0.93, 1.4).
These beta distributions lead to functional uniform priors on the non-linear parameters of the model,
ED50 and h, which result in uniform distributions over the possible functional shapes of the dose-response
curve (see [31] for details).
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B Simulation results for subgroup identification
Table 8: Subgroup identification metrics for scenarios with n = 500 (100 per group) and k = 10
covariates.
scenario method |S| |Sˆ| non.null sens spec ppv npv
null oracle 0.00 14.00 0.03 0.97 0.00 1.00
noshrink 0.00 41.90 0.96 0.92 0.00 1.00
hs 0.00 14.85 0.10 0.97 0.00 1.00
hs dep 0.00 15.16 0.10 0.97 0.00 1.00
rhs 0.00 14.73 0.10 0.97 0.00 1.00
rhs dep 0.00 14.91 0.10 0.97 0.00 1.00
sas 0.00 14.01 0.04 0.97 0.00 1.00
sas dep 0.00 14.75 0.04 0.97 0.00 1.00
only progn. oracle 0.00 11.00 0.02 0.98 0.00 1.00
noshrink 0.00 43.73 0.97 0.91 0.00 1.00
hs 0.00 16.51 0.21 0.97 0.00 1.00
hs dep 0.00 18.08 0.26 0.96 0.00 1.00
rhs 0.00 16.53 0.22 0.97 0.00 1.00
rhs dep 0.00 18.17 0.26 0.96 0.00 1.00
sas 0.00 22.12 0.21 0.96 0.00 1.00
sas dep 0.00 16.78 0.13 0.97 0.00 1.00
progn. & pred. oracle 175.29 150.00 1.00 0.78 0.96 0.93 0.90
noshrink 175.29 107.94 1.00 0.51 0.94 0.84 0.79
hs 175.29 138.05 0.93 0.62 0.91 0.84 0.84
hs dep 175.29 149.93 0.98 0.68 0.91 0.84 0.86
rhs 175.29 139.04 0.93 0.62 0.91 0.84 0.84
rhs dep 175.29 149.99 0.98 0.68 0.91 0.84 0.86
sas 175.29 118.19 0.80 0.50 0.91 0.80 0.79
sas dep 175.29 132.30 0.86 0.58 0.91 0.81 0.82
only pred. oracle 175.60 154.13 1.00 0.82 0.97 0.95 0.92
noshrink 175.60 107.77 1.00 0.51 0.95 0.85 0.78
hs 175.60 167.12 1.00 0.84 0.94 0.90 0.92
hs dep 175.60 167.23 1.00 0.83 0.94 0.90 0.92
rhs 175.60 167.91 1.00 0.84 0.94 0.90 0.92
rhs dep 175.60 167.64 1.00 0.83 0.93 0.90 0.92
sas 175.60 168.73 1.00 0.86 0.95 0.92 0.93
sas dep 175.60 165.19 1.00 0.84 0.94 0.91 0.92
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C Comparison to model-based recursive partitioning: fur-
ther simulation results
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Figure 5: Distribution of RMSE over 1000 simulated trials for treatment effect predictions averaged
over patients and doses. with n = 500 (100 per group) and k = 10 covariates for different functional
forms in scenarios with prognostic and predictive covariates.
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Table 9: Subgroup identification metrics for scenarios with n = 500 (100 per group) and k = 10
covariates for different functional forms in scenarios with prognostic and predictive covariates.
functional form method |S| |Sˆ| non.null sens spec ppv npv
linear oracle 175.29 150.00 1.00 0.78 0.96 0.93 0.90
noshrink 175.29 107.94 1.00 0.51 0.94 0.84 0.79
null 175.29 42.50 0.09 0.09 0.92 0.36 0.65
hs 175.29 138.05 0.93 0.62 0.91 0.84 0.84
hs dep 175.29 149.93 0.98 0.68 0.91 0.84 0.86
rhs 175.29 139.04 0.93 0.62 0.91 0.84 0.84
rhs dep 175.29 149.99 0.98 0.68 0.91 0.84 0.86
sas 175.29 118.19 0.80 0.50 0.91 0.80 0.79
sas dep 175.29 132.30 0.86 0.58 0.91 0.81 0.82
mob 175.29 178.85 0.93 0.60 0.77 0.64 0.80
interaction oracle 203.49 169.93 1.00 0.76 0.95 0.93 0.86
noshrink 203.49 115.49 1.00 0.33 0.83 0.58 0.64
null 203.49 147.50 0.29 0.29 0.70 0.41 0.59
hs 203.49 139.31 1.00 0.40 0.81 0.60 0.66
hs dep 203.49 140.42 1.00 0.40 0.80 0.59 0.66
rhs 203.49 141.43 1.00 0.41 0.81 0.60 0.67
rhs dep 203.49 142.05 1.00 0.42 0.81 0.60 0.67
sas 203.49 148.80 0.99 0.41 0.78 0.57 0.66
sas dep 203.49 146.77 1.00 0.40 0.78 0.57 0.66
mob 203.49 201.92 0.87 0.55 0.70 0.62 0.73
logistic oracle 139.85 119.49 0.92 0.67 0.93 0.85 0.89
noshrink 139.85 74.13 1.00 0.33 0.92 0.64 0.78
null 139.85 18.00 0.04 0.04 0.96 0.29 0.72
hs 139.85 104.61 0.77 0.44 0.88 0.67 0.82
hs dep 139.85 100.95 0.82 0.44 0.89 0.70 0.82
rhs 139.85 97.97 0.75 0.41 0.89 0.68 0.82
rhs dep 139.85 96.38 0.82 0.42 0.90 0.70 0.82
sas 139.85 101.88 0.68 0.39 0.87 0.57 0.81
sas dep 139.85 82.34 0.60 0.32 0.90 0.60 0.79
mob 139.85 164.16 0.74 0.54 0.75 0.48 0.84
step function oracle 124.90 100.54 0.60 0.58 0.92 0.79 0.89
noshrink 124.90 65.50 0.98 0.26 0.91 0.50 0.79
null 124.90 16.50 0.03 0.03 0.97 0.25 0.75
hs 124.90 109.97 0.76 0.45 0.86 0.56 0.85
hs dep 124.90 94.02 0.71 0.38 0.88 0.58 0.83
rhs 124.90 99.50 0.72 0.40 0.87 0.57 0.84
rhs dep 124.90 84.96 0.70 0.34 0.89 0.58 0.82
sas 124.90 110.14 0.74 0.41 0.84 0.48 0.83
sas dep 124.90 87.09 0.58 0.32 0.87 0.49 0.82
mob 124.90 127.23 0.53 0.44 0.81 0.44 0.85
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Supporting Material
In the following additional simulations results from the simulation study in Section 4 of the main article
for scenarios with smaller sample size (n = 250) or larger number of covariates (k = 30) are depicted. For
details on the setup of the simulation study and the metrics used see the main article.
A Estimation of individual treatment effect curves
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Figure 1: Distribution of RMSE over 1000 simulated trials for treatment effect predictions averaged
over patients and doses. with n = 500 (100 per group) and k = 30 covariates
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Figure 2: Distribution of RMSE over 1000 simulated trials for treatment effect predictions averaged
over patients and doses with n = 250 (50 per group) and k = 10 covariates
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Figure 3: Distribution of RMSE over 1000 simulated trials for treatment effect predictions averaged
over patients and doses with n = 250 (50 per group) and k = 30 covariates
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B Selection of predictive covariates
39
Table 1: Rel. frequency of covariates being selected as having effects on E0, Emax and ED50 with
n = 250 (50 per group) and k = 10 covariates. Variables selected with oracle are the correct
covariates.
E0 ED50 Emax
scenario method x1 x2 x3 x4 x1 x2 x3 x4 x1 x2 x3 x4
null oracle 0 0 0 0 0 0 0 0 0 0 0 0
noshrink 0.52 0.53 0.54 0.53 0.47 0.47 0.47 0.49 0.46 0.45 0.47 0.48
hs 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
hs dep 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
rhs 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
rhs dep 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
sas 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
sas dep 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
only progn. oracle 1 1 1 0 0 0 0 0 0 0 0 0
noshrink 1.00 1.00 0.90 0.52 0.46 0.46 0.47 0.47 0.51 0.46 0.47 0.48
hs 0.98 0.98 0.65 0.02 0.00 0.00 0.00 0.00 0.01 0.01 0.01 0.00
hs dep 0.99 0.99 0.81 0.06 0.00 0.00 0.00 0.00 0.01 0.01 0.01 0.00
rhs 0.98 0.98 0.66 0.02 0.00 0.00 0.00 0.00 0.01 0.01 0.01 0.00
rhs dep 0.99 0.99 0.80 0.06 0.00 0.00 0.00 0.00 0.01 0.01 0.00 0.00
sas 0.93 0.92 0.29 0.00 0.01 0.01 0.01 0.00 0.05 0.05 0.03 0.00
sas dep 0.97 0.98 0.36 0.00 0.01 0.00 0.01 0.00 0.01 0.01 0.01 0.00
progn. & pred. oracle 1 1 1 0 0 1 1 0 0 1 1 0
noshrink 1.00 1.00 0.72 0.53 0.47 0.73 0.74 0.50 0.51 0.84 0.81 0.48
hs 0.95 0.80 0.02 0.01 0.00 0.03 0.01 0.00 0.03 0.24 0.05 0.00
hs dep 0.97 0.97 0.09 0.03 0.00 0.04 0.01 0.00 0.02 0.33 0.05 0.00
rhs 0.95 0.78 0.02 0.01 0.00 0.03 0.01 0.00 0.03 0.25 0.04 0.00
rhs dep 0.97 0.97 0.08 0.03 0.00 0.04 0.01 0.00 0.03 0.36 0.05 0.00
sas 0.89 0.68 0.01 0.00 0.02 0.12 0.03 0.00 0.08 0.32 0.06 0.00
sas dep 0.96 0.80 0.03 0.00 0.01 0.12 0.02 0.00 0.03 0.27 0.05 0.00
only pred. oracle 0 0 0 0 0 1 1 0 0 1 1 0
noshrink 0.57 0.66 0.66 0.54 0.47 0.73 0.73 0.46 0.45 0.83 0.83 0.48
hs 0.00 0.11 0.11 0.00 0.00 0.07 0.09 0.00 0.00 0.51 0.51 0.00
hs dep 0.00 0.14 0.13 0.00 0.00 0.07 0.08 0.00 0.00 0.47 0.48 0.00
rhs 0.00 0.12 0.11 0.00 0.00 0.09 0.10 0.00 0.01 0.53 0.54 0.01
rhs dep 0.00 0.14 0.14 0.00 0.00 0.07 0.08 0.00 0.00 0.49 0.50 0.00
sas 0.00 0.07 0.06 0.00 0.00 0.42 0.41 0.00 0.00 0.72 0.73 0.00
sas dep 0.00 0.16 0.18 0.00 0.00 0.27 0.27 0.00 0.00 0.52 0.53 0.00
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Table 2: Rel. frequency of covariates being selected as having effects on E0, Emax and ED50 with
n = 500 (100 per group) and k = 30 covariates. Variables selected with oracle are the correct
covariates.
E0 ED50 Emax
scenario method x1 x2 x3 x4 x1 x2 x3 x4 x1 x2 x3 x4
null oracle 0 0 0 0 0 0 0 0 0 0 0 0
noshrink 0.53 0.55 0.54 0.55 0.48 0.47 0.49 0.46 0.53 0.49 0.50 0.53
hs 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
hs dep 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
rhs 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
rhs dep 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
sas 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
sas dep 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
only progn. oracle 1 1 1 0 0 0 0 0 0 0 0 0
noshrink 1.00 1.00 0.97 0.53 0.45 0.45 0.47 0.48 0.52 0.49 0.51 0.52
hs 0.99 0.99 0.84 0.00 0.00 0.00 0.01 0.00 0.01 0.01 0.01 0.00
hs dep 1.00 1.00 0.90 0.01 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00
rhs 0.99 0.99 0.84 0.00 0.00 0.00 0.01 0.00 0.01 0.01 0.01 0.00
rhs dep 1.00 1.00 0.90 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
sas 0.98 0.98 0.63 0.00 0.01 0.01 0.03 0.00 0.01 0.02 0.05 0.00
sas dep 0.99 0.99 0.69 0.00 0.00 0.00 0.01 0.00 0.01 0.01 0.01 0.00
progn. & pred. oracle 1 1 1 0 0 1 1 0 0 1 1 0
noshrink 1.00 1.00 0.75 0.53 0.48 0.78 0.80 0.46 0.50 0.92 0.89 0.50
hs 0.99 0.88 0.02 0.00 0.00 0.09 0.02 0.00 0.01 0.36 0.13 0.00
hs dep 1.00 1.00 0.16 0.00 0.01 0.18 0.05 0.00 0.01 0.69 0.19 0.00
rhs 0.99 0.87 0.02 0.00 0.00 0.10 0.03 0.00 0.01 0.37 0.12 0.00
rhs dep 1.00 1.00 0.15 0.00 0.01 0.20 0.07 0.00 0.02 0.70 0.18 0.00
sas 0.97 0.76 0.02 0.00 0.01 0.21 0.07 0.00 0.03 0.36 0.12 0.00
sas dep 0.99 0.96 0.13 0.00 0.01 0.34 0.12 0.00 0.01 0.56 0.18 0.00
only pred. oracle 0 0 0 0 0 1 1 0 0 1 1 0
noshrink 0.54 0.79 0.78 0.54 0.49 0.77 0.78 0.49 0.51 0.90 0.88 0.51
hs 0.00 0.04 0.06 0.00 0.00 0.26 0.28 0.00 0.00 0.87 0.84 0.00
hs dep 0.00 0.07 0.07 0.00 0.00 0.24 0.24 0.00 0.00 0.84 0.83 0.00
rhs 0.00 0.04 0.06 0.00 0.00 0.27 0.28 0.00 0.00 0.88 0.86 0.00
rhs dep 0.00 0.06 0.07 0.00 0.00 0.24 0.25 0.00 0.00 0.86 0.84 0.00
sas 0.00 0.04 0.04 0.00 0.00 0.74 0.77 0.00 0.00 0.94 0.94 0.00
sas dep 0.00 0.08 0.10 0.00 0.00 0.64 0.64 0.00 0.00 0.88 0.85 0.00
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Table 3: Rel. frequency of covariates being selected as having effects on E0, Emax and ED50 with
n = 250 (50 per group) and k = 30 covariates. Variables selected with oracle are the correct
covariates.
E0 ED50 Emax
scenario method x1 x2 x3 x4 x1 x2 x3 x4 x1 x2 x3 x4
null oracle 0 0 0 0 0 0 0 0 0 0 0 0
noshrink 0.54 0.54 0.52 0.57 0.39 0.39 0.42 0.39 0.50 0.48 0.51 0.50
hs 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
hs dep 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
rhs 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
rhs dep 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
sas 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
sas dep 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
only progn. oracle 1 1 1 0 0 0 0 0 0 0 0 0
noshrink 1.00 1.00 0.89 0.56 0.40 0.39 0.42 0.39 0.47 0.51 0.49 0.51
hs 0.98 0.98 0.46 0.01 0.00 0.00 0.00 0.00 0.01 0.01 0.00 0.00
hs dep 0.99 1.00 0.52 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
rhs 0.98 0.98 0.46 0.01 0.00 0.00 0.00 0.00 0.01 0.01 0.00 0.00
rhs dep 0.99 1.00 0.51 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
sas 0.92 0.91 0.24 0.00 0.02 0.03 0.01 0.00 0.05 0.06 0.02 0.00
sas dep 0.97 0.97 0.29 0.00 0.01 0.00 0.00 0.00 0.01 0.01 0.00 0.00
progn. & pred. oracle 1 1 1 0 0 1 1 0 0 1 1 0
noshrink 1.00 1.00 0.62 0.55 0.43 0.55 0.55 0.38 0.51 0.75 0.75 0.50
hs 0.95 0.76 0.00 0.00 0.00 0.02 0.00 0.00 0.02 0.21 0.01 0.00
hs dep 0.97 0.98 0.02 0.00 0.00 0.04 0.01 0.00 0.01 0.28 0.02 0.00
rhs 0.96 0.75 0.00 0.00 0.00 0.03 0.01 0.00 0.02 0.22 0.01 0.00
rhs dep 0.97 0.98 0.02 0.00 0.00 0.05 0.01 0.00 0.02 0.31 0.02 0.00
sas 0.91 0.68 0.00 0.00 0.02 0.15 0.02 0.00 0.06 0.31 0.03 0.00
sas dep 0.96 0.81 0.02 0.00 0.00 0.12 0.01 0.00 0.02 0.27 0.02 0.00
only pred. oracle 0 0 0 0 0 1 1 0 0 1 1 0
noshrink 0.53 0.76 0.75 0.57 0.41 0.55 0.56 0.42 0.51 0.73 0.74 0.51
hs 0.00 0.11 0.12 0.00 0.00 0.06 0.07 0.00 0.00 0.43 0.41 0.00
hs dep 0.00 0.15 0.15 0.00 0.00 0.05 0.06 0.00 0.00 0.36 0.34 0.00
rhs 0.00 0.11 0.12 0.00 0.00 0.07 0.08 0.00 0.00 0.46 0.42 0.00
rhs dep 0.00 0.16 0.15 0.00 0.00 0.05 0.06 0.00 0.00 0.37 0.35 0.00
sas 0.00 0.07 0.06 0.00 0.00 0.36 0.39 0.00 0.00 0.65 0.65 0.00
sas dep 0.00 0.14 0.16 0.00 0.00 0.21 0.22 0.00 0.00 0.44 0.41 0.00
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C Subgroup identification
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Table 4: Subgroup identification metrics for scenarios with n = 250 (50 per group) and k = 10
covariates.
scenario method |S| |Sˆ| non.null sens spec ppv npv
null oracle 0.00 14.75 0.06 0.94 0.00 1.00
noshrink 0.00 30.48 0.98 0.88 0.00 1.00
hs 0.00 14.62 0.18 0.94 0.00 1.00
hs dep 0.00 15.45 0.18 0.94 0.00 1.00
rhs 0.00 15.08 0.19 0.94 0.00 1.00
rhs dep 0.00 15.32 0.18 0.94 0.00 1.00
sas 0.00 14.26 0.09 0.94 0.00 1.00
sas dep 0.00 14.78 0.07 0.94 0.00 1.00
only progn. oracle 0.00 14.75 0.06 0.94 0.00 1.00
noshrink 0.00 29.41 0.98 0.88 0.00 1.00
hs 0.00 21.89 0.34 0.91 0.00 1.00
hs dep 0.00 21.82 0.35 0.91 0.00 1.00
rhs 0.00 22.28 0.35 0.91 0.00 1.00
rhs dep 0.00 21.88 0.34 0.91 0.00 1.00
sas 0.00 27.76 0.41 0.89 0.00 1.00
sas dep 0.00 21.49 0.28 0.91 0.00 1.00
progn. & pred. oracle 87.87 68.82 0.99 0.68 0.95 0.91 0.86
noshrink 87.87 50.76 1.00 0.42 0.91 0.74 0.75
hs 87.87 63.77 0.82 0.48 0.87 0.76 0.78
hs dep 87.87 67.91 0.89 0.53 0.87 0.78 0.80
rhs 87.87 63.88 0.82 0.48 0.87 0.76 0.78
rhs dep 87.87 67.66 0.89 0.53 0.87 0.78 0.80
sas 87.87 62.92 0.71 0.42 0.84 0.68 0.75
sas dep 87.87 60.41 0.73 0.42 0.86 0.71 0.76
only pred. oracle 87.27 71.26 1.00 0.75 0.97 0.95 0.89
noshrink 87.27 49.73 1.00 0.42 0.92 0.74 0.75
hs 87.27 74.21 0.97 0.68 0.91 0.87 0.87
hs dep 87.27 73.51 0.96 0.68 0.91 0.87 0.86
rhs 87.27 74.69 0.97 0.69 0.91 0.87 0.87
rhs dep 87.27 73.56 0.96 0.67 0.91 0.87 0.86
sas 87.27 77.80 0.99 0.75 0.92 0.88 0.89
sas dep 87.27 71.36 0.94 0.66 0.91 0.86 0.85
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Table 5: Subgroup identification metrics for scenarios with n = 500 (100 per group) and k = 30
covariates.
scenario method |S| |Sˆ| non.null sens spec ppv npv
null oracle 0.00 9.50 0.02 0.98 0.00 1.00
noshrink 0.00 70.34 1.00 0.86 0.00 1.00
hs 0.00 10.23 0.08 0.98 0.00 1.00
hs dep 0.00 10.82 0.07 0.98 0.00 1.00
rhs 0.00 10.20 0.08 0.98 0.00 1.00
rhs dep 0.00 10.50 0.07 0.98 0.00 1.00
sas 0.00 10.13 0.03 0.98 0.00 1.00
sas dep 0.00 9.41 0.02 0.98 0.00 1.00
only progn. oracle 0.00 13.33 0.03 0.97 0.00 1.00
noshrink 0.00 70.60 1.00 0.86 0.00 1.00
hs 0.00 20.09 0.16 0.96 0.00 1.00
hs dep 0.00 20.83 0.23 0.96 0.00 1.00
rhs 0.00 19.62 0.16 0.96 0.00 1.00
rhs dep 0.00 20.27 0.22 0.96 0.00 1.00
sas 0.00 28.67 0.22 0.94 0.00 1.00
sas dep 0.00 20.44 0.16 0.96 0.00 1.00
progn. & pred. oracle 175.91 147.92 1.00 0.77 0.96 0.94 0.90
noshrink 175.91 99.73 1.00 0.37 0.90 0.66 0.73
hs 175.91 110.30 0.80 0.45 0.91 0.81 0.78
hs dep 175.91 139.46 0.95 0.61 0.90 0.82 0.83
rhs 175.91 110.84 0.81 0.46 0.91 0.81 0.78
rhs dep 175.91 139.53 0.96 0.61 0.90 0.82 0.83
sas 175.91 104.31 0.66 0.39 0.89 0.74 0.75
sas dep 175.91 123.99 0.84 0.52 0.90 0.79 0.80
only pred. oracle 87.27 71.26 1.00 0.75 0.97 0.95 0.89
noshrink 87.27 49.73 1.00 0.42 0.92 0.74 0.75
hs 87.27 74.21 0.97 0.68 0.91 0.87 0.87
hs dep 87.27 73.51 0.96 0.68 0.91 0.87 0.86
rhs 87.27 74.69 0.97 0.69 0.91 0.87 0.87
rhs dep 87.27 73.56 0.96 0.67 0.91 0.87 0.86
sas 87.27 77.80 0.99 0.75 0.92 0.88 0.89
sas dep 87.27 71.36 0.94 0.66 0.91 0.86 0.85
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Table 6: Subgroup identification metrics for scenarios with n = 250 (50 per group) and k = 30
covariates.
scenario method |S| |Sˆ| non.null sens spec ppv npv
null oracle 0.00 13.25 0.05 0.95 0.00 1.00
noshrink 0.00 42.36 1.00 0.83 0.00 1.00
hs 0.00 14.30 0.12 0.94 0.00 1.00
hs dep 0.00 14.37 0.12 0.94 0.00 1.00
rhs 0.00 14.21 0.13 0.94 0.00 1.00
rhs dep 0.00 14.32 0.12 0.94 0.00 1.00
sas 0.00 15.12 0.08 0.94 0.00 1.00
sas dep 0.00 13.85 0.07 0.94 0.00 1.00
only progn. oracle 0.00 15.75 0.06 0.94 0.00 1.00
noshrink 0.00 43.22 1.00 0.83 0.00 1.00
hs 0.00 21.37 0.28 0.91 0.00 1.00
hs dep 0.00 21.46 0.28 0.91 0.00 1.00
rhs 0.00 20.80 0.27 0.92 0.00 1.00
rhs dep 0.00 21.17 0.28 0.92 0.00 1.00
sas 0.00 29.95 0.38 0.88 0.00 1.00
sas dep 0.00 22.39 0.26 0.91 0.00 1.00
progn. and pred. oracle 87.81 67.24 0.99 0.67 0.95 0.91 0.86
noshrink 87.81 51.95 1.00 0.32 0.86 0.55 0.70
hs 87.81 54.20 0.65 0.37 0.87 0.71 0.75
hs con 87.81 61.66 0.80 0.45 0.87 0.75 0.77
rhs 87.81 54.16 0.66 0.37 0.87 0.71 0.75
rhs con 87.81 61.37 0.81 0.45 0.87 0.76 0.77
sas 87.81 57.26 0.62 0.37 0.85 0.65 0.74
sas con 87.81 55.47 0.67 0.38 0.86 0.70 0.75
only pred. oracle 87.73 71.61 1.00 0.75 0.96 0.95 0.89
noshrink 87.73 52.25 1.00 0.33 0.85 0.55 0.70
hs 87.73 74.12 0.93 0.65 0.90 0.84 0.85
hs dep 87.73 72.64 0.92 0.64 0.90 0.85 0.85
rhs 87.73 74.50 0.94 0.65 0.90 0.84 0.85
rhs dep 87.73 72.37 0.92 0.63 0.90 0.84 0.85
sas 87.73 78.09 0.96 0.72 0.91 0.86 0.88
sas dep 87.73 69.65 0.89 0.61 0.90 0.84 0.84
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